Developer docs
API playgroundTry for free, no card

Search company profiles

BioFi

Full company profile

uuid002k77c

Namestring
BioFi
Legal namestring
BioFi AG
Websiteurl
biofi.ch
Company typeenum
Private
Founded yearstring
-
Descriptiontext

BioFi AG is a Basel, Switzerland-based private biotech software company that operates from the Novartis Campus with an eight-person team. It targets pharmaceutical and biotechnology companies and builds computational tools aimed at reducing translational risk in drug discovery. The company's core offering is EndoGenics™, a mechanism-based modeling and simulation platform developed from first principles; its computational core, the Endogenics Simulation Engine (ESE), was launched in July 2025. The platform integrates multi-omics inputs—including targeted plasma proteomics, bulk RNA-seq, longitudinal biomarker trajectories, and multi-cohort validation datasets—to build directed mechanistic networks and simulate relative system behavior under different target perturbations, enabling target validation, mechanism-of-action characterization, and patient stratification.

BioFi's product strategy is anchored on addressing the industry-wide 8.4% clinical trial success rate by moving from static, pattern-based prediction to dynamic causal simulation. A second product, EndoClinics™, is in development as a clinical-outcome UI initially focused on post-acute COVID-19 complications under the Horizon Europe–funded POINT project. The company's moat rests on its proprietary simulation architecture, multi-omics data integration, and a specialized team spanning computational science, bioinformatics, and software engineering.

BioFi monetizes through fee-based software services and non-exclusive commercial model licenses, with contracts priced in Swiss Francs under multi-year terms as referenced in its Terms of Service. Go-to-market is direct enterprise engagement via contact forms, email (contact@biofi.ch), and "Partner with Us" calls to action, supplemented by content marketing (blog, newsletter via MailerLite) and event participation through collaborator networks. No customer logos, pricing tiers, or revenue figures are disclosed, and the EndoGenics platform is still labeled Beta, indicating a pre-commercial or early-pilot commercial stage.

Short descriptiontext

BioFi AG is a Basel-based biotech software company building the EndoGenics™ simulation platform, using causal, omics-constrained disease modeling to help pharmaceutical and biotechnology companies validate targets, characterize mechanisms of action, and stratify patients for clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
disease simulation software, mechanism-based modeling, drug discovery analytics, omics data integration, computational biology platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Software Publishers51321
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery & Computational Biology Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fee-Based Software Services
TypeSubscription Recurring
Description

Some services or models may require payment, as described in specific conditions. Terms of Service Section 6.2 indicates fee-based services exist. Non-exclusive commercial licenses are granted for fee-based models. Payment terms are in Swiss Francs (CHF).

biofi.ch
2Fee-Based Models License
TypeLicensing Royalties
Description

Non-exclusive, commercial license granted for fee-based models under Section 2.2 of Terms of Service.

biofi.ch
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Fee-based services available with specific conditions
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Specific conditions included where services are offered or in corresponding Service Agreement. All currency references in Swiss Francs (CHF).

biofi.ch
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1EndoGenics™
Description

A mechanism-based modeling and simulation platform developed from first principles. Includes the Endogenics Simulation Engine (ESE) for modeling and simulating complex biological processes.

biofi.ch
+1 more record
Core offering1 text field

BioFi develops and licenses the EndoGenics platform, a mechanism-based modeling and simulation software that ingests multi-omics data (proteomics, RNA-seq, biomarker trajectories) to build causal disease network models, simulate target perturbations, and predict downstream molecular evolution. The platform is aimed at pharmaceutical and biotechnology R&D teams for target identification, Mechanism of Action characterization, and patient stratification. Access is delivered as enterprise software under multi-year fee-based license and subscription agreements denominated in Swiss Francs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Overall drug clinical trial success rate is 8.4% - target validation without clinical context and insufficient mechanistic understanding are identified as major reasons for high clinical attrition
+1 more record
Product overview1 text field

BioFi offers a platform-based approach centered on EndoGenics™, a mechanism-based modeling and simulation platform currently in Beta. EndoGenics™ is powered by the Endogenics Simulation Engine (ESE), which handles the computational simulation of disease network dynamics. A forthcoming module called EndoClinics™ is designed to provide a customized interface for clinical outcome insights. Together, these products enable cross-functional teams to generate, simulate, and analyze causal disease models from omics data within days.

Product and service1 record
1EndoGenics
CategoryDrug Discovery & Computational Biology Software
Description

Mechanism-based modeling and simulation platform that lets pharmaceutical and biotech R&D teams generate disease models from multi-omics data, simulate signal propagation over time, test mechanistic hypotheses, and predict downstream molecular evolution. Currently in Beta, delivered as enterprise software with account creation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

The POINT (Post-acute fOllow-up of non-communicable disease InTerventions) project is a Horizon Europe funded initiative. BioFi participates in developing innovative strategies for prevention and management of non-communicable diseases arising as complications during the post-acute phase of COVID-19. This represents a significant research collaboration with EU funding and co-development of disease management strategies.

Strategic tierMinorTypeOthers
Description

Listed as a collaborator and supporter on BioFi's website. SERI is Switzerland's federal institute supporting innovation and technology transfer.

3Region of Denmark
Strategic tierMinorTypeOthers
Description

Listed as a collaborator and supporter. Regional government body that may provide regional support and innovation funding.

biofi.ch
Strategic tierMinorTypeOthers
Description

Listed as a collaborator and supporter. Innovation hub and economic development agency for the Basel region supporting life sciences companies.

5University of Copenhagen (UCPH)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a collaborator. University partnership providing academic research collaboration and access to bioinformatics expertise and omics data resources.

biofi.ch
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a collaborator. University partnership for research collaboration in bioinformatics and life sciences.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insitro combines ML with high-throughput biology and multi-omic data to model disease biology for pharma partners — closely comparable to BioFi in target identification, mechanistic modeling, and patient stratification use cases.

TypeEmerging player
Description

Turbine builds a simulation platform that models cancer biology to identify targets and combination therapies — overlaps with BioFi's simulation-driven mechanistic approach for pharma R&D.

TypeDirect peer
Description

Schrödinger provides physics-based computational software (including AI-augmented workflows) for molecular simulation and drug discovery — directly comparable to BioFi's EndoGenics Simulation Engine approach as scientific modeling software for pharma.

TypeDirect peer
Description

Owkin uses AI and multi-omics patient data to inform drug development and clinical trial design — comparable to BioFi in causal disease modeling, patient stratification, and multi-omic biomarker integration.

TypeDirect peer
Description

Recursion operates an AI/ML-driven drug discovery platform combining high-throughput biology with computational modeling. Although broader in scope, both companies share the AI-enabled biology platform business model targeting pharma R&D.

TypeBroad incumbent
Description

Certara is a leading provider of biosimulation and modeling software for drug development — comparable as a broader incumbent offering mechanism-aware modeling and simulation tools to pharma R&D teams.

TypeDirect peer
Description

Aitia (formerly GNS Healthcare) builds causal AI and 'Digital Twins' for drug discovery using multi-omics data — directly comparable to BioFi's mechanism-based causal simulation approach for target identification and MoA characterization.

TypeEmerging player
Description

CytoReason builds AI-driven computational disease models integrating multi-omics and clinical data for pharma R&D — directly comparable to BioFi in using multi-omics data to model disease biology and guide drug discovery.

TypeDirect peer
Description

Insilico Medicine is an AI-driven drug discovery company using generative and predictive ML for target identification and chemistry — comparable to BioFi as a competing AI platform positioned to reduce clinical trial attrition.

TypeBroad incumbent
Description

BenevolentAI operates an AI discovery platform combining knowledge graphs and ML for target identification — overlaps BioFi's target ID & validation positioning with a broader, more established (and Europe-based) commercial footprint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioFi

Drug Discovery & Computational Biology Softwarebiofi.ch

BioFi AG is a Basel-based biotech software company building the EndoGenics™ simulation platform, using causal, omics-constrained disease modeling to help pharmaceutical and biotechnology companies validate targets, characterize mechanisms of action, and stratify patients for clinical trials.

What BioFi does

BioFi AG is a Basel, Switzerland-based private biotech software company that operates from the Novartis Campus with an eight-person team. It targets pharmaceutical and biotechnology companies and builds computational tools aimed at reducing translational risk in drug discovery. The company's core offering is EndoGenics™, a mechanism-based modeling and simulation platform developed from first principles; its computational core, the Endogenics Simulation Engine (ESE), was launched in July 2025. The platform integrates multi-omics inputs—including targeted plasma proteomics, bulk RNA-seq, longitudinal biomarker trajectories, and multi-cohort validation datasets—to build directed mechanistic networks and simulate relative system behavior under different target perturbations, enabling target validation, mechanism-of-action characterization, and patient stratification.

BioFi's product strategy is anchored on addressing the industry-wide 8.4% clinical trial success rate by moving from static, pattern-based prediction to dynamic causal simulation. A second product, EndoClinics™, is in development as a clinical-outcome UI initially focused on post-acute COVID-19 complications under the Horizon Europe–funded POINT project. The company's moat rests on its proprietary simulation architecture, multi-omics data integration, and a specialized team spanning computational science, bioinformatics, and software engineering.

BioFi monetizes through fee-based software services and non-exclusive commercial model licenses, with contracts priced in Swiss Francs under multi-year terms as referenced in its Terms of Service. Go-to-market is direct enterprise engagement via contact forms, email (contact@biofi.ch), and "Partner with Us" calls to action, supplemented by content marketing (blog, newsletter via MailerLite) and event participation through collaborator networks. No customer logos, pricing tiers, or revenue figures are disclosed, and the EndoGenics platform is still labeled Beta, indicating a pre-commercial or early-pilot commercial stage.

BioFi firmographics

Firmographics
Name
BioFi
Legal name
BioFi AG
Website
https://biofi.ch
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
BioFi AG is a Basel-based biotech software company building the EndoGenics™ simulation platform, using causal, omics-constrained disease modeling to help pharmaceutical and biotechnology companies validate targets, characterize mechanisms of action, and stratify patients for clinical trials.
Ownership category
akta.pro rank

BioFi industry classification

Industry
Product category
Drug Discovery & Computational Biology Software
NAICS
Software Publishers (51321), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Disease simulation software
  • Mechanism-based modeling
  • Drug discovery analytics
  • Omics data integration
  • Computational biology platform

Where BioFi is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

BioFi business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Fee-Based Software Services: Some services or models may require payment, as described in specific conditions. Terms of Service Section 6.2 indicates fee-based services exist. Non-exclusive commercial licenses are granted for fee-based models. Payment terms are in Swiss Francs (CHF).
  2. Fee-Based Models License: Non-exclusive, commercial license granted for fee-based models under Section 2.2 of Terms of Service.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractFee-based services available with specific conditions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

BioFi product offering

Product offering

Core offering

BioFi develops and licenses the EndoGenics platform, a mechanism-based modeling and simulation software that ingests multi-omics data (proteomics, RNA-seq, biomarker trajectories) to build causal disease network models, simulate target perturbations, and predict downstream molecular evolution. The platform is aimed at pharmaceutical and biotechnology R&D teams for target identification, Mechanism of Action characterization, and patient stratification. Access is delivered as enterprise software under multi-year fee-based license and subscription agreements denominated in Swiss Francs.

Product overview

BioFi offers a platform-based approach centered on EndoGenics™, a mechanism-based modeling and simulation platform currently in Beta. EndoGenics™ is powered by the Endogenics Simulation Engine (ESE), which handles the computational simulation of disease network dynamics. A forthcoming module called EndoClinics™ is designed to provide a customized interface for clinical outcome insights. Together, these products enable cross-functional teams to generate, simulate, and analyze causal disease models from omics data within days.

Differentiator

Problem solved

Functional benefit

Brands

  • EndoGenics™: A mechanism-based modeling and simulation platform developed from first principles. Includes the Endogenics Simulation Engine (ESE) for modeling and simulating complex biological processes.
  • EndoClinics™

Products and services

  • EndoGenics Mechanism-based modeling and simulation platform that lets pharmaceutical and biotech R&D teams generate disease models from multi-omics data, simulate signal propagation over time, test mechanistic hypotheses, and predict downstream molecular evolution. Currently in Beta, delivered as enterprise software with account creation.

Quantifiable outcome

  • Overall drug clinical trial success rate is 8.4% - target validation without clinical context and insufficient mechanistic understanding are identified as major reasons for high clinical attrition
  • +1 more outcomes

Companies that use BioFi

Customer profile

Segments2 records

Ideal customer profiles1 record

BioFi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

BioFi partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • European Commission (POINT Project)coreStrategic or Co-development Partner · 1 June 2024The POINT (Post-acute fOllow-up of non-communicable disease InTerventions) project is a Horizon Europe funded initiative. BioFi participates in developing innovative strategies for prevention and management of non-communicable diseases arising as complications during the post-acute phase of COVID-19. This represents a significant research collaboration with EU funding and co-development of disease management strategies.
  • Swiss Economic Institute (SERI)minorOthersListed as a collaborator and supporter on BioFi's website. SERI is Switzerland's federal institute supporting innovation and technology transfer.
  • Region of DenmarkminorOthersListed as a collaborator and supporter. Regional government body that may provide regional support and innovation funding.
  • Basel AreaminorOthersListed as a collaborator and supporter. Innovation hub and economic development agency for the Basel region supporting life sciences companies.
  • University of Copenhagen (UCPH)coreStrategic or Co-development PartnerListed as a collaborator. University partnership providing academic research collaboration and access to bioinformatics expertise and omics data resources.
  • University of TartucoreStrategic or Co-development PartnerListed as a collaborator. University partnership for research collaboration in bioinformatics and life sciences.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

BioFi competitors and assessment

Company assessment

Direct peers

  • Insitro: Insitro combines ML with high-throughput biology and multi-omic data to model disease biology for pharma partners — closely comparable to BioFi in target identification, mechanistic modeling, and patient stratification use cases.
  • Schrödinger: Schrödinger provides physics-based computational software (including AI-augmented workflows) for molecular simulation and drug discovery — directly comparable to BioFi's EndoGenics Simulation Engine approach as scientific modeling software for pharma.
  • Owkin: Owkin uses AI and multi-omics patient data to inform drug development and clinical trial design — comparable to BioFi in causal disease modeling, patient stratification, and multi-omic biomarker integration.
  • Recursion Pharmaceuticals: Recursion operates an AI/ML-driven drug discovery platform combining high-throughput biology with computational modeling. Although broader in scope, both companies share the AI-enabled biology platform business model targeting pharma R&D.
  • Aitia: Aitia (formerly GNS Healthcare) builds causal AI and 'Digital Twins' for drug discovery using multi-omics data — directly comparable to BioFi's mechanism-based causal simulation approach for target identification and MoA characterization.
  • Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company using generative and predictive ML for target identification and chemistry — comparable to BioFi as a competing AI platform positioned to reduce clinical trial attrition.

Emerging players

  • Turbine AI: Turbine builds a simulation platform that models cancer biology to identify targets and combination therapies — overlaps with BioFi's simulation-driven mechanistic approach for pharma R&D.
  • CytoReason: CytoReason builds AI-driven computational disease models integrating multi-omics and clinical data for pharma R&D — directly comparable to BioFi in using multi-omics data to model disease biology and guide drug discovery.

Broad incumbents

  • Certara: Certara is a leading provider of biosimulation and modeling software for drug development — comparable as a broader incumbent offering mechanism-aware modeling and simulation tools to pharma R&D teams.
  • BenevolentAI: BenevolentAI operates an AI discovery platform combining knowledge graphs and ML for target identification — overlaps BioFi's target ID & validation positioning with a broader, more established (and Europe-based) commercial footprint.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

BioFi social profiles

Digital presence

BioFi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioFi leadership team

Management profile

Number of profiles

Profiles8 records

BioFi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioFi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioFi

What does BioFi do?

BioFi develops and licenses the EndoGenics platform, a mechanism-based modeling and simulation software that ingests multi-omics data (proteomics, RNA-seq, biomarker trajectories) to build causal disease network models, simulate target perturbations, and predict downstream molecular evolution. The platform is aimed at pharmaceutical and biotechnology R&D teams for target identification, Mechanism of Action characterization, and patient stratification. Access is delivered as enterprise software under multi-year fee-based license and subscription agreements denominated in Swiss Francs.

Is BioFi a public or private company?

BioFi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioFi founded?

BioFi was founded in -1. It employs 1 to 10 people.

Where is BioFi based?

BioFi is headquartered in Basel, Switzerland, in the Europe region.

How does BioFi make money?

Two revenue lines are on record. Fee-Based Software Services are the primary driver. The others are fee-Based Models License.

Who are BioFi's main competitors?

Direct peers on record are Insitro, Schrödinger, Owkin, Recursion Pharmaceuticals, Aitia and Insilico Medicine. Emerging players are Turbine AI and CytoReason. Broad incumbents are Certara and BenevolentAI.

Does BioFi have an API?

No public API is recorded for BioFi.

What industry is BioFi in?

BioFi's product category is Drug Discovery & Computational Biology Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 51321 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales